Dr. Reddy’s Laboratories announced the first-to-market launch of Bosutinib Tablets 400mg in the United States on June 13, 2026. This generic equivalent of Bosulif® expands the company’s oncology portfolio and enhances patient access to affordable treatments. The launch is a result of a collaboration with MSN Laboratories, with Dr. Reddy’s holding exclusive marketing rights in the US. The product is eligible for 180-days of generic drug exclusivity.
First-to-Market Launch in US
Dr. Reddy’s Laboratories Ltd., along with its subsidiaries, has officially announced the first-to-market launch of Bosutinib Tablets 400mg in the United States. This significant event took place on June 13, 2026. The newly launched product is a generic equivalent of Bosulif® and marks an expansion of Dr. Reddy’s oncology portfolio, reinforcing the company’s commitment to improving patient access to affordable and high-quality medicines.
Collaboration and Exclusivity
This launch was made possible through a collaboration with MSN Laboratories Private Limited, a prominent pharmaceutical company in India responsible for the development and manufacturing of the product. Dr. Reddy’s Laboratories holds the exclusive marketing rights for Bosutinib Tablets 400mg in the United States. The product is recognized as a first-to-file product and is therefore eligible for 180 days of generic drug exclusivity for this particular strength in the U.S. market.
Market Significance and Strategy
Milan Kalawadia, CEO of North America for Dr. Reddy’s Laboratories, Inc., highlighted the launch’s significance, stating, “This launch highlights our commitment to leading with timely market entry for high-priority therapies while broadening access for both patients and healthcare providers. With this launch, we remain focused on strengthening our oncology portfolio and partnering across the healthcare system to ensure that critical treatments are both accessible and affordable.” The Bosulif® brand generated approximately $253.8 million in U.S. sales for the 12-month period ending April 2026, according to IQVIA data, indicating a substantial market for this therapeutic area.
Product Details
The product launched is Bosutinib Tablets 400mg, categorized under Oncology (Tyrosine Kinase Inhibitor). The launch targets the international market, specifically the United States. The launch date was June 13, 2026.
Source: BSE
